Image For Activity Cover
GREQH2EM2405 - CME/CMLE - HER2 Testing in Other Solid Tumors and Implications for Treatment
Course Description

Updates in HER2-directed Therapies in Solid Tumors 

Activity Description: 

This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in pan-tumor HER2 testing in patients with advanced solid tumors and of treatment options based on HER2 results. This activity will also address designing laboratory workflows to achieve efficient, accurate, and equitable pan-tumor HER2 testing. The microlearning design of this activity allows for a brief and focused exploration of this topic. 

Course topics include: 

  • HER2 signaling pathway 

  • HER2 amplification and overexpression and its prevalence in various solid tumors 

  • DESTINY-PanTumor02 and the recent FDA pan-tumor approval 

  • HER2 IHC scoring guidelines 

  • Specimen handing and biomarker reporting 

  • HER2 IHC with different antibodies and tumor heterogeneity 

  • Treatment implications for patients based on HER2 results 

Faculty/Authors

Wei Zhang, MD, PhD
Associate Professor, Medical Director of Molecular Pathology (Solid Tumor)
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center
Kansas City, Kansas 

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement 

CME/CMLE Credit: 0.25
Estimated Completion Time: 0.25 hour
Format: Online educational activity 


Target Audience  

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.

 
Credit Designation Statement 

The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.  

ASCP designates this activity for a maximum of .25 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.  

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. 

 
Method of Participation  

To complete the activity and receive credit, the participant must have participated in the course. CME certificates will be provided online 

Commercial Support 

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. 

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content and click the first module of the course.
  3. Complete the Demographic Survey.
  4. Complete the Pre-Test.
  5. Review the Educational Activity.
  6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
  7. Submit the course Evaluation.
  8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.
Faculty Disclosure

Release Dates:
10/21/2024  
Review Date:
Expiration Date: 10/21/2027  

 

Course Objectives

Upon completion of this activity, you will be able to:

  • Identify when HER2 testing may be indicated in patients with advanced solid tumors
  • Describe how the use of certain HER2-directed therapy may impact clinical outcomes in patients with different types of solid tumors 
  • Outline how HER2 testing may be performed in different types of solid tumors
  • Design laboratory workflows to achieve efficient, accurate, and equitable pan-tumor HER2 testing
  • Lead collaborative efforts with members of the clinical and laboratory teams to establish HER2 testing decision trees and protocols 
Summary
Availability: On-Demand
Credit Offered:
0.25 CME/CMLE Credit
Powered By